Eli Groppo, MD
Otolaryngology · Sacramento, CANPI 1245402338
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Optinose US, Inc. at 58.4% of the total. Reporting peaked in 2019 at $4,019 and has fallen 84.9% since, to $606 in 2025.
Across 59 payments — averaging $110.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$4K
- Regeneron Healthcare Solutions, Inc.$421
- Stryker$399
- Cochlear Americas$310
- Intersect ENT, Inc.$281
- Sanofi$257
- plus $1K from 12 others
Across 9 payments — averaging $5995.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Optinose US, Inc.$54K
What the payments were for
- Consulting fees$3,00046%
- Travel & lodging$4567%
- Food & beverage$3,02347%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 13 | $3,794 |
| Regeneron Healthcare Solutions, Inc. | 5 | $421 |
| Stryker | 7 | $399 |
| Cochlear Americas | 2 | $310 |
| Intersect ENT, Inc. | 5 | $281 |
| Sanofi | 7 | $257 |
| Aerin Medical Inc. | 3 | $234 |
| Integra Lifesciences Corporation | 3 | $164 |
| KARL Storz Endoscopy-america | 1 | $163 |
| Medtronic | 3 | $130 |
| Johnson & Johnson | 1 | $88 |
| Inspire Medical Systems, Inc. | 1 | $75 |
| Merck | 2 | $57 |
| GSK | 2 | $47 |
| Zimmer Biomet | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Acclarent, Inc | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$3,456
- DUPIXENT$482
- INTEGRA$352
- Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode$310
- Baha$310
- OSIA OSI300 IMPLANT$310
- VIVAER STYLUS$183
- RHINAER STYLUS$183
- Solo+ TTD Handpiece$163
- NASOPORE$158
- LATERA$158
- SCOPIS ENT$158
- CLARIFIX CRYOTHERAPY DEVICE$158
- XPRESS ENT DILATION SYSTEM$158
- SINUVA$119
- INTEGRA DERMAL REGENERATION TEMPLATE$117
- PRIMATRIX$117
How this compares
$6,492 in reported general payments places this provider in the 85th percentile of 1,021 otolaryngology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XhanceFluticasone Propionate | 14 | $13,765 |
| Ipratropium Bromide | 103 | $3,633 |
| Mometasone Furoate | 14 | $2,856 |
| Hydrocortisone-Acetic AcidHydrocortisone/Acetic Acid | 18 | $2,696 |
| Fluticasone Propionate | 113 | $2,162 |
| Fluocinolone Acetonide Oil | 35 | $1,102 |
| Budesonide | 16 | $902 |
| Azelastine Hcl | 19 | $548 |
| Montelukast Sodium | 36 | $348 |
| Pantoprazole Sodium | 27 | $338 |
| Mupirocin | 28 | $226 |
| Clarithromycin | 11 | $185 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $114 |
| Levothyroxine Sodium | 11 | $89 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $86 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $3,794 | $13,76514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,021 otolaryngology providers in California.
Other otolaryngology in Sacramento
- Edward StrongSacramento$82K
- Travis TollefsonSacramento$60K
- Scott McCuskerSacramento$38K
- Brian WeeksSan Diego$924K
- Randall OwRoseville$613K
- Amir MoradiVista$389K
- Keith BlackwellLos Angeles$349K
- Kalpna DurairajSun Valley$348K
- Todd MillerNewport Beach$259K
- Jeffrey SuhLos Angeles$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.